Gruss E, Portolés J, Tato A, Hernández T, López-Sánchez P, Velayos P, Gago M C, Martínez S, Andrés M M, Sánchez Tornero J, Jiménez P
Servicio de Nefrología, Fundación Hospital Alcorcón, Madrid, Spain.
Nefrologia. 2009;29(2):123-9. doi: 10.3265/Nefrologia.2009.29.2.4954.en.full.
Tunneled catheters in hemodialysis are associated with poor prognosis, however, few prospective studies have been designed to specifically evaluate this aspect. The objective has been evaluate the impact of tunneled catheter in patient mortality and costs attributable to this procedure.
A seven years prospective cohort study was performed in all patients starting hemodialysis in our health care area adjusting for comorbidity and albumin. The study comprised 260 patients with Charlson index 7.05 +/- 2.8 (age 65.5 years, 62.3% males, 25% with diabetes mellitus and 37.7% with a previous cardiovascular event.
The first vascular access was a catheter in 47.3%, PTFE in 11.2% and native arteriovenous fistula in 41.5%. Minimum follow-up was one year, with an average of 2.31 years/patient. The mortality risk adjusted for comorbidity was greater among the patients that started with catheterization, HR: 1.86 [1.11-3.05]. This negative effect was observed in 57.30% of those subjected to catheterization at any stage (HR: 1.68 [1.00-2.84] and proved to be time dependent, i.e., the longer catheterization, the greater the risk: HR: 7.66 [3.34-17.54] third versus first tertil. The cost directly attributable to catheter use was 563.31 euros/month. All poor prognosis groups showed lower albumin and hemoglobin levels, without differences in efficacy.
Tunneled catheter use at any time is associated with an increased risk of death. This effect increases with the duration of catheterization, both circumstances are independent of patient comorbidity at time start of hemodialysis and implies a higher net cost.
血液透析中的带隧道导管与预后不良相关,然而,很少有前瞻性研究专门设计用于评估这一方面。目的是评估带隧道导管对患者死亡率以及该操作所致成本的影响。
在我们医疗保健区域内对所有开始血液透析的患者进行了一项为期七年的前瞻性队列研究,并对合并症和白蛋白进行了校正。该研究包括260例患者,Charlson指数为7.05±2.8(年龄65.5岁,男性占62.3%,25%患有糖尿病,37.7%既往有心血管事件)。
首次血管通路为导管的占47.3%,聚四氟乙烯(PTFE)的占11.2%,自体动静脉内瘘的占41.5%。最短随访时间为1年,平均每位患者2.31年。经合并症校正后的死亡风险在以导管插入术开始的患者中更高,风险比(HR):1.86[1.11 - 3.05]。在任何阶段接受导管插入术的患者中有57.30%观察到这种负面影响(HR:1.68[1.00 - 2.84]),并且被证明是时间依赖性的,即导管插入时间越长,风险越大:第三三分位数与第一三分位数相比,HR:7.66[3.34 - 17.54]。导管使用直接导致的成本为每月563.31欧元。所有预后不良组的白蛋白和血红蛋白水平较低,疗效无差异。
任何时候使用带隧道导管都与死亡风险增加相关。这种影响随着导管插入时间的延长而增加,这两种情况均独立于血液透析开始时患者的合并症,并且意味着更高的净成本。